Table 2.

Pulmonary function and asthma severity stratified by age of asthma onset and atopic status in children and adults.

Children, Early Onset (n=320)	NAA		AANFS		AAFS		P value
Children, Early Onset (n=320)	N	Mean ± SD	N	Mean ± SD	N	Mean ± SD	AAFS vs. AANFS	AAFS vs. NAA	AANFS vs. NAA
Baseline FEV₁ % predicted	40	97 ± 12	132	91 ± 17	148	86 ± 19	0.014	0.0002	0.047
Baseline FVC % predicted	40	103 ± 12	132	102 ± 14	148	100 ± 17	0.15	0.18	0.87
Baseline FEV₁/FVC	40	0.82 ± 0.07	132	0.78 ± 0.10	148	0.74 ± 0.10	0.0013	<0.0001	0.02
Maximal FEV1 % predicted	39	107 ± 12	132	105 ± 15	148	102 ± 17	0.14	0.038	0.28
Maximal FVC % predicted	39	108 ± 13	130	110 ± 15	148	109 ± 17	0.72	061	0.37
Maximal Reversibility	39	13 ± 10	132	18 ± 19	148	21 ± 17	0.01	0.0035	0.33
PC₂₀ methacholine, mg/mL	19	4.5 (1.1, 9.5)	70	1.3 (0.6, 4.0)	61	0.6 (0.3, 2.0)	0.014	0.001	0.028
ATS-ERS severe asthma, n (%)	40	17 (43)	132	78 (59)	148	91 (61)	0.71	0.047	0.072
Exacerbations in the last 12 months, n (%)	40	22 (55)	130	70 (54)	148	84 (57)	0.63	0.86	1
ACQ-6	13	1.31 ± 1.11	71	1.23 ± 1.16	92	1.32 ± 1.37	0.95	0.75	0.68
Adults, Early Onset (n=683)	NAA		AANFS		AAFS		P value
Adults, Early Onset (n=683)	N	Mean ± SD	N	Mean ± SD	N	Mean ± SD	AAFS vs. AANFS	AAFS vs. NAA	AANFS vs. NAA
Baseline FEV₁ % predicted	62	74 ± 24	345	75 ± 21	276	75 ± 21	0.65	0.86	0.69
Baseline FVC % predicted	60	82 ± 19	344	88 ± 19	274	89 ± 18	0.69	0.017	0.026
Baseline FEV₁/FVC	60	0.72 ± 0.14	344	0.70 ± 0.11 1	275	0.69 ± 0.12	0.33	0.017	0.059
Maximal FEV1 % predicted	61	84 ± 22	343	88 ± 19	272	87 ± 19	0.67	0.45	0.31
Maximal FVC % predicted	59	90 ± 16	342	97 ± 17	272	97 ± 16	0.64	0.0013	0.0038
Maximal Reversibility	61	16 ± 19	343	19 ± 20	272	18 ± 18	0.69	0.02	0.012
PC₂₀ methacholine, mg/mL	29	2.6 (0.6, 4.9)	196	1.1 (0.4, 3.4)	167	0.9 (0.3, 2.7)	0.16	0.02	0.09
ATS-ERS severe asthma, n (%)	62	38 (61)	345	137 (40)	276	103 (37)	0.56	0.0009	0.002
Exacerbations in the last 12 months, n (%)	62	28 (45)	343	81 (24)	276	62 (22)	0.77	0.0004	0.0009
ACQ-6	27	1.74 ± 1.29	122	1.55 ± 1.37	97	1.20 ± 1.14	0.06	0.038	0.34
Adults, Late Onset (n=670)	NAA		AANFS		AAFS		P value
Adults, Late Onset (n=670)	N	Mean ± SD	N	Mean ± SD	N	Mean ± SD	AAFS vs. AANFS	AAFS vs. NAA	AANFS vs. NAA
Baseline FEV₁ % predicted	163	73 ± 23	347	74 ± 20	160	73 ± 21	0.61	0.73	0.43
Baseline FVC % predicted	163	82 ± 19	347	84 ± 17	159	85 ± 18	0.67	0.093	0.13
Baseline FEV₁/FVC	163	0.70 ± 0.12	347	0.70 ± 0.12	159	0.69 ± 0.12	0.16	0.26	0.95
Maximal FEV1 % predicted	163	83 ± 21	346	86 ± 19	159	86 ± 20	0.89	0.13	0.085
Maximal FVC % predicted	163	89 ± 17	346	93 ± 16	159	95 ± 15	0.09	0.0006	0.02
Maximal Reversibility	163	17 ± 18	346	17 ± 17	159	18 ± 16	0.33	0.29	0.85
PC₂₀ methacholine, mg/mL	71	2.5 (0.8, 5.8)	181	1.6 (0.5, 4.8)	85	1.1 (0.4, 3.7)	0.31	0.016	0.08
ATS-ERS severe asthma, n (%)	163	92 (56)	347	151(44)	160	78 (49)	0.29	0.18	0.0077
Exacerbations in the last 12 months, n (%)	163	57 (35)	346	91 (26)	160	37 (23)	0.51	0.02	0.047
ACQ-6	84	1.43 ± 1.43	135	1.16 ± 1.20	55	1.27 ± 1.10	0.34	0.87	0.27

NAA: non-atopic asthma; AANFS: atopic asthma with non-fungal sensitization; AAFS: atopic asthma with fungal sensitization.